COVID-19 and pirfenidone. A case report

Abstract

Diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF) has been greatly inflfl uenced by the COVID-19 pandemic. Not only has it impacted the prognosis of the Idiopathic Pulmonary Fibrosis, but also the approach to treating these patients. The aim of this study was to evaluate our patient who got infected with COVID-19 and after hospitalization the underling, not previously diagnosed idiopathic pulmonary fifi brosis was suspected in this patient. Due to COVID-19 infection and suspected idiopathic pulmonary fifi brosis the patient was administered Pirfenidon to treat the deep fifi brotic changes. The case was studied during the period from November 2020 – July 2021 in ”Vivamedi” hospital Tbilisi, Georgia. The systemic review was made using available literature from online libraries like PubMed, Google Scholar and UpToDate. The report was prepared after analysing all laboratory results and other radiological investigations that were performed during the course of treatment. The patient was treated mainly with Oxygen therapy, Pirfenidone and anticoagulants. The patient recovered from COVID-19 with minimal pulmonary fifi brotic changes. The vitals of the patient were stabilised and the lab results returned to normal. The patient was discharged from the hospital after 10 days and fully recovered from the viral infection. The survival after COVID-19 pneumonia in a patient with newly diagnosed IPF under antififi brotic + treatment without serious deterioration is a novel case. Antififi brotics which are available or developing not only have a role in treating such cases but can also be valuable in treating severe COVID-19 in patients without IPF, and might also be helpful preventing pulmonary fifi brosis after SARS-CoV-2 infection.